| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 02/24/2005 | US20050042690 Diagnosis and management of infection caused by chlamydia |
| 02/24/2005 | US20050042687 Methods and compositions for treating hematological disorders using 9118, 990, 17662, 81982, 630, 21472, 17692, 19290, 21620, 21689, 28899, 53659, 64549, 9465, 23544, 7366, 27417, 57259, 21844, 943, 2061, 5891, 9137, 13908, 14310, 17600, 25584, 27824, 28469, 38947, 53003, 965, 56639, 9661, 16052, 1521, 6662, 13913, 12405 or 5014 |
| 02/24/2005 | US20050042683 Expression vector comprising nucleotide sequences coding serum response element receptor (SERB-2) for use in identifying modulator for prevention and treatment of nervous system disorders |
| 02/24/2005 | US20050042680 Single chain antigen-binding polypeptides for polymer conjugation |
| 02/24/2005 | US20050042667 Expression vector comprising nucleotide sequences coding polypeptide for use in diagnosis, treatment and prevention of immune, hematopoietic, inflammatory and tumor diseases |
| 02/24/2005 | US20050042659 Secreted soluble alpha2delta-2, alpha2delta-3, or alpha2delta-4 calcium channel subunit polypeptides and screening assays using same |
| 02/24/2005 | US20050042655 Using hematopoietoic regulatory related polypeptide (HEMA) for use in diagnosis, treatment and prevention of hematopoietic disorders |
| 02/24/2005 | US20050042653 Human transport protein homologs |
| 02/24/2005 | US20050042652 Identifying monoclonal antibody for use in prevention and treatment of skin disorers; immunotherapy and peptide mimetics |
| 02/24/2005 | US20050042643 Elavl-1 |
| 02/24/2005 | US20050042637 Pax-encoding vector and use thereof |
| 02/24/2005 | US20050042635 Prophylactic and therapeutic benefits of a new class of immune stimulating peptides |
| 02/24/2005 | US20050042634 B. anthracis prevention and treatment: mutant B. anthracis lacking luxS activity and furanone inhibition of growth, AI-2 quorum sensing, and toxin production |
| 02/24/2005 | US20050042631 Cloning and characterization of two novel m-RNA transcription factors |
| 02/24/2005 | US20050042624 Tumor antigen |
| 02/24/2005 | US20050042616 Screening hepatocarcinoma-6 nucleotide sequences to identify mutagenic variation; determining sensitivity of individual to liver cancer; cancer diagnosis |
| 02/24/2005 | US20050042613 Nucleic acids having expression differentails between hepatoblastoma and normal liver |
| 02/24/2005 | US20050042606 Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
| 02/24/2005 | US20050042603 Protein fusion comprising nuclear localization signal domain for use as tool to enhance gene transfer into cells: gene therapy and heterologous gene expression |
| 02/24/2005 | US20050042602 Monitoring immunologic, Hematologic and inflammatory diseases |
| 02/24/2005 | US20050042600 Using complex formed with carboxymethylcysteine substituted peptide as diagnostic indicator of viral infection; diagnosing cell proliferative and infectious disorders; immunodiagnostics |
| 02/24/2005 | US20050042599 Using complex formed with carboxymethylcysteine substituted peptide as diagnostic indicator of viral infection; diagnosing cell proliferative and infectious disorders immunodiagnostics |
| 02/24/2005 | US20050042295 Anti-angiogenic compositions and methods of use |
| 02/24/2005 | US20050042273 Covalently linking PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex; diagnostic and therapeutic agent; improving pharmacokinetic properties |
| 02/24/2005 | US20050042272 Vesiles derived from t cells, production and uses |
| 02/24/2005 | US20050042235 Borrelia burgdorferi bacterin |
| 02/24/2005 | US20050042234 Method |
| 02/24/2005 | US20050042231 Useful in vaccines, and monoclonal antibodies against said immunogenic surface proteins; hybridoma cell line that produes said antibodies; use in diagnostic kits for determining presence, onset, or decrease in Leptospiral infection |
| 02/24/2005 | US20050042230 Administering respiratory syncytial virus G protein immunogen or fragment |
| 02/24/2005 | US20050042229 Influenza hemagglutinin and neuraminidase variants |
| 02/24/2005 | US20050042227 drug biological conjugates used in the diagnosis, prophylaxis, or treatment of nervous system disorders or lysosomal storage diseases; drug delivery; blood brain barriers |
| 02/24/2005 | US20050042226 Treatment of chronic human viral hepatitis |
| 02/24/2005 | US20050042224 Methods and products related to metabolic interactions in disease |
| 02/24/2005 | US20050042222 Methods of diagnosing thyroid carcinoma |
| 02/24/2005 | US20050042221 Purified antibody directed against modified beta -amyloid peptide comprising malondialdehyde adduct; medical research involving amyloid precursor protein (APP)-metabolism; enzyme-linked immunosorbent assays |
| 02/24/2005 | US20050042220 Antigen binding fragments; rheumatoid arthritis, osteoarthritis, multiple sclerosis, myasthenia gravis, Crohn*s disease, inflammatory bowel disease, lupus, diabetes, psoriasis, asthma, chronic obstructive pulmonary disease, cardiovascular inflammation, pancreatitis, hepatitis, and nephritis |
| 02/24/2005 | US20050042218 Vaccines for treating and/or preventing cancer, infections, autoimmune diseases, and/or allergies |
| 02/24/2005 | US20050042217 Contacting a target cell expressing target cell-specific antigen with an expression vector encoding a CD8 polypeptide comprising the CD8 alpha -chain; extending survival of transplant allografts and treating graft versus host disease |
| 02/24/2005 | US20050042214 Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis |
| 02/24/2005 | US20050042209 Enhancing the induction apoptosis in a MUC1 expressing cancer cell by a pro-apoptotic drugs; antiproliferative agents |
| 02/24/2005 | US20050042208 Incubating precursor cell capable of differentiating to cytotoxic T cell with antigen presenting cell in presence of substance having binding activity to CD44, fibronectin, regulator of signal emitted by growth factor, and/or inhibitor of binding to growth factor receptor; immunotherapy |
| 02/24/2005 | US20050042205 Purification and cloning of receptors for luteinizing hormone, choriogonadotropin, follicle stimulating hormone, and/or thyroid stimulating hormone; fertility, breast or prostate cancer, benign prostatic hypertrophy, vasomotor instability, osteoporosis, and polycystic ovarian disease; genetic engineering |
| 02/24/2005 | US20050042203 Induction of antibodies against a hepatitis B surface antigen by sequential injection of bupivacaine and of a plasmid carrying a gene coding antigen; vaccine containing bare DNA is injected into host previously treated with substance capable of inducing coagulating necrosis of muscle fibers |
| 02/24/2005 | US20050042201 Synergistic mixture of glycoprotein and angiogenesis inhibitor comprising angiostatin, thrombostatin, endostatin, interferon, interferon-inducible factor 10, platelet factor, and/or cyclooxygenase inhibitor; antitumor and anticarcinogenic agents |
| 02/24/2005 | US20050042199 Comprising interleukin-2 (IL-2) and tlp peptides ( Tumour Liberated Particles) protein complexes; antitumor and anticarcinogenic agents; immunotherapy |
| 02/24/2005 | DE20122302U1 Variante des Modifizierten Vaccinia-Ankara-Virus Modified version of the vaccinia Ankara virus |
| 02/24/2005 | CA2852159A1 Metabolically engineered bacterial strains having non-functional endogenous gluconate transporters |
| 02/24/2005 | CA2762015A1 Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| 02/24/2005 | CA2575926A1 Canine specific growth hormone releasing hormone |
| 02/24/2005 | CA2536235A1 Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics |
| 02/24/2005 | CA2536146A1 Splice variants of erbb ligands, compositions and uses thereof |
| 02/24/2005 | CA2536008A1 Apparatus and method for the selective assembly of protein |
| 02/24/2005 | CA2535901A1 Ups as modifiers of the beta catenin pathway and methods of use |
| 02/24/2005 | CA2535863A1 Polypeptides of streptococcus pyogenes |
| 02/24/2005 | CA2535670A1 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 02/24/2005 | CA2535508A1 A new class of .alpha.2.delta. calcium channel subunits |
| 02/24/2005 | CA2535261A1 Prion-specific peptide reagents |
| 02/24/2005 | CA2535007A1 Nogo receptor antagonists |
| 02/24/2005 | CA2534474A1 Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| 02/24/2005 | CA2534467A1 New diabetes type 2 animal model |
| 02/24/2005 | CA2534436A1 Antagonistic analogs of gh-rh (2003) |
| 02/24/2005 | CA2532576A1 Npc1l1 (npc3) and methods of use thereof |
| 02/24/2005 | CA2532027A1 Specific binding agents to hepatocyte growth factor |
| 02/24/2005 | CA2528514A1 Improved recombinant human interferon-beta-1b polypeptides |
| 02/24/2005 | CA2526595A1 Metabolically engineered bacterial strains having non-functional endogenous gluconate transporters |
| 02/24/2005 | CA2526339A1 Polyvalent immunogen |
| 02/24/2005 | CA2526146A1 Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens |
| 02/24/2005 | CA2525969A1 Intron fusion proteins, and methods of identifying and using same |
| 02/24/2005 | CA2525647A1 Synthetic chemokine receptor ligands and methods of use thereof |
| 02/24/2005 | CA2504532A1 Botulinum neurotoxin b receptors and use thereof |
| 02/23/2005 | EP1508620A1 Circular DNA molecule with conditional origin of replication, method for preparing same and use thereof in gene therapy |
| 02/23/2005 | EP1508615A1 Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics |
| 02/23/2005 | EP1508614A1 Human neuronal nicotinic acetylcholine receptor compositions and methods employing same |
| 02/23/2005 | EP1508574A2 Long wavelength engineered fluorescent proteins |
| 02/23/2005 | EP1508572A1 PROTEIN INDUCING CELL DEATH OF i HELICOBACTER PYLORI /i |
| 02/23/2005 | EP1508340A1 Insulin resistance improving agents |
| 02/23/2005 | EP1508339A1 Tuberculosis vaccine |
| 02/23/2005 | EP1508273A1 Adiponectin-knoucout nonhuman animal |
| 02/23/2005 | EP1508047A2 Method for identifying immunoreactive peptides |
| 02/23/2005 | EP1508043A2 Antigenic targets of autoimmune sensorineural hearing loss (aisnhl) and development of tests fro diagnosis and management of aisnhl |
| 02/23/2005 | EP1507869A2 Improved receptor detection |
| 02/23/2005 | EP1507862A2 Modified tetracycline repressor protein compositions and methods of use |
| 02/23/2005 | EP1507861A2 Vaccines |
| 02/23/2005 | EP1507851A1 Method for assembling sub units into capsoides |
| 02/23/2005 | EP1507802A1 Transformed fungi for production of recombinant proteins |
| 02/23/2005 | EP1507800A1 Use of monocarboxylate transporter protein for thyroid hormone transport |
| 02/23/2005 | EP1507799A2 Novel cyclic peptides and use thereof as anti-microbial agents |
| 02/23/2005 | EP1507798A1 Export and modification of (poly)peptides in the lantibiotic way |
| 02/23/2005 | EP1507797A2 Inhibitors of proteins from the rho-gef family |
| 02/23/2005 | EP1507795A1 Tumour-associated peptides that bond to mhc molecules |
| 02/23/2005 | EP1507794A2 Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments |
| 02/23/2005 | EP1507793A2 Neutrokine-alpha and neutrokine-alpha splice variant |
| 02/23/2005 | EP1507790A2 Human genes and gene expression products isolated from human prostate |
| 02/23/2005 | EP1507787A2 Prostate cancer-related compositions, methods, and kits based on dna macroarray proteomics platforms |
| 02/23/2005 | EP1507550A1 Suicide tetramers comprising mhc class i and uses thereof |
| 02/23/2005 | EP1311280A4 Cell internalized peptide-drug conjugates |
| 02/23/2005 | EP1035870B1 Compositions and methods for treatment of hepatitis c virus-associated diseases |
| 02/23/2005 | EP0783524B1 Peptides and pharmaceutical compositions comprising them |
| 02/23/2005 | CN1584032A Protein coding sequence of protein kinase 3 activated by cell division protoplasm for brassia rape |
| 02/23/2005 | CN1584030A Long-noded pit viper poison dissolving fiber protein No.2 gene and use thereof |